Bicycle Therapeutics plc (ADR)
General ticker "BCYC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $663.5M (TTM average)
Bicycle Therapeutics plc (ADR) does not follow the US Stock Market performance with the rate: -2.4%.
Estimated limits based on current volatility of 2.2%: low 6.39$, high 6.68$
Factors to consider:
- Total employees count: 305 (+7.4%) as of 2024
- Top business risk factors: Operating losses, Need for additional capital, Product liability, Geopolitical risks, Regulatory and compliance
- Current price 20.1% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.50$, 23.30$]
- 2025-12-31 to 2026-12-31 estimated range: [8.15$, 20.23$]
Financial Metrics affecting the BCYC estimates:
- Positive: with PPE of -5.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.37 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 82.88 > 64.17
- Positive: Investing cash flow per share per price, % of -0.15 > -0.62
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.20 <= 0.74
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BCYC quotes
Long-term BCYC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $14.46MM | $26.98MM | $35.27MM |
| Operating Expenses | $131.12MM | $216.92MM | $245.15MM |
| Operating Income | $-116.65MM | $-189.95MM | $-209.87MM |
| Non-Operating Income | $2.41MM | $10.74MM | $36.08MM |
| Interest Expense | $3.34MM | $3.26MM | $1.73MM |
| R&D Expense | $81.61MM | $156.50MM | $172.97MM |
| Income(Loss) | $-114.24MM | $-179.21MM | $-173.80MM |
| Taxes | $-1.52MM | $1.46MM | $-4.76MM |
| Profit(Loss)* | $-112.72MM | $-180.66MM | $-169.03MM |
| Stockholders Equity | $270.78MM | $370.93MM | $793.06MM |
| Assets | $410.61MM | $595.34MM | $956.87MM |
| Operating Cash Flow | $-86.11MM | $-60.63MM | $-164.72MM |
| Capital expenditure | $18.99MM | $2.93MM | $1.24MM |
| Investing Cash Flow | $-18.99MM | $-2.93MM | $-1.24MM |
| Financing Cash Flow | $6.69MM | $250.03MM | $519.75MM |
| Earnings Per Share** | $-3.80 | $-5.08 | $-2.90 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.